Literature DB >> 12401719

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.

Josephine M Forbes1, Mark E Cooper, Vicki Thallas, Wendy C Burns, Merlin C Thomas, Gail C Brammar, Fiona Lee, Sharon L Grant, Louise M Burrell, Louise A Burrell, George Jerums, Tanya M Osicka.   

Abstract

The effect of ACE inhibition on the formation of advanced glycation end products (AGEs) and oxidative stress was explored. Streptozocin-induced diabetic animals were randomized to no treatment, the ACE inhibitor ramipril (3 mg/l), or the AGE formation inhibitor aminoguanidine (1 g/l) and followed for 12 weeks. Control groups were followed concurrently. Renal AGE accumulation, as determined by immunohistochemistry and both serum and renal fluorescence, were increased in diabetic animals. This was attenuated by both ramipril and aminoguanidine to a similar degree. Nitrotyrosine, a marker of protein oxidation, also followed a similar pattern. The receptor for AGEs, gene expression of the membrane-bound NADPH oxidase subunit gp91phox, and nuclear transcription factor-kappaB were all increased by diabetes but remained unaffected by either treatment regimen. Two other AGE receptors, AGE R2 and AGE R3, remained unchanged for the duration of the study. The present study has identified a relationship between the renin-angiotensin system and the accumulation of AGEs in experimental diabetic nephropathy that may be linked through oxidative stress

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401719     DOI: 10.2337/diabetes.51.11.3274

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  70 in total

Review 1.  Pathogenesis of diabetic nephropathy.

Authors:  Claudia van Dijk; Tomas Berl
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 2.  Antiproteinuric effect of RAS blockade: new mechanisms.

Authors:  Markus Lassila; Mark E Cooper; Karin Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

Review 3.  Trends in advanced glycation end products research in diabetes mellitus and its complications.

Authors:  José D Méndez; Jianling Xie; Montserrat Aguilar-Hernández; Verna Méndez-Valenzuela
Journal:  Mol Cell Biochem       Date:  2010-03-23       Impact factor: 3.396

4.  Clinical efficacy of 'Spleen-kidney-care' Yiqi Huayu and Jiangzhuo traditional Chinese medicine for the treatment of patients with diabetic nephropathy.

Authors:  Hong Liu; Jin Zheng; Rong-Heng Li
Journal:  Exp Ther Med       Date:  2015-07-07       Impact factor: 2.447

5.  A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease.

Authors:  Francesca Polverino; Maria E Laucho-Contreras; Hans Petersen; Vanesa Bijol; Lynette M Sholl; Mary E Choi; Miguel Divo; Victor Pinto-Plata; Alfredo Chetta; Yohannes Tesfaigzi; Bartolomé R Celli; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2017-06-01       Impact factor: 21.405

6.  Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells.

Authors:  Natalia Mercer; Hafiz Ahmed; Susana B Etcheverry; Gerardo R Vasta; Ana Maria Cortizo
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

Review 7.  Advanced-glycation end products in insulin-resistant states.

Authors:  Georgia Soldatos; Mark E Cooper; Karin A M Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

8.  Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.

Authors:  B J Davis; C I Johnston; L M Burrell; W C Burns; E Kubota; Z Cao; M E Cooper; T J Allen
Journal:  Diabetologia       Date:  2003-06-28       Impact factor: 10.122

9.  LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats.

Authors:  J L Figarola; S Scott; S Loera; C Tessler; P Chu; L Weiss; J Hardy; S Rahbar
Journal:  Diabetologia       Date:  2003-07-05       Impact factor: 10.122

Review 10.  RAGE: a novel target for drug intervention in diabetic vascular disease.

Authors:  Barry I Hudson; Ann Marie Schmidt
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.